Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. 2013

João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Murcia, Spain.

Primary prevention of cardiovascular disease (CVD) aims to avoid a first event in subjects that are at risk but have not yet been diagnosed with heart disease. Secondary prevention of CVD aims to avoid new events in patients with established heart disease. Both approaches involve clinical intervention and implementation of healthy lifestyles. The grape and wine polyphenol resveratrol (3,5,4'-trihydroxy-trans-stilbene) has shown cardioprotective benefits in humans. Most of these approaches deal with rather high doses and short follow-ups, and do not address the issue of long-term resveratrol consumption safety, especially in medicated individuals. Here, we review the trials conducted with resveratrol in patients at risk for or with established CVD, focusing on the two longest human clinical trials reported so far (1-year follow-up). We also discuss the expectations for resveratrol from a dietary and clinical perspective in relation to CVD. However, statistically significant changes in CVD-risk markers do not necessarily equal clinical significance in the daily care of patients.

UI MeSH Term Description Entries
D011322 Primary Prevention Specific practices for the prevention of disease or mental disorders in susceptible individuals or populations. These include HEALTH PROMOTION, including mental health; protective procedures, such as COMMUNICABLE DISEASE CONTROL; and monitoring and regulation of ENVIRONMENTAL POLLUTANTS. Primary prevention is to be distinguished from SECONDARY PREVENTION and TERTIARY PREVENTION. Prevention, Primary,Disease Prevention, Primary,Prevention, Primordial,Primordial Prevention,Disease Preventions, Primary,Preventions, Primordial,Primary Disease Prevention,Primary Disease Preventions,Primordial Preventions
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077185 Resveratrol A stilbene and non-flavonoid polyphenol produced by various plants including grapes and blueberries. It has anti-oxidant, anti-inflammatory, cardioprotective, anti-mutagenic, and anti-carcinogenic properties. It also inhibits platelet aggregation and the activity of several DNA HELICASES in vitro. 3,4',5-Stilbenetriol,3,4',5-Trihydroxystilbene,3,5,4'-Trihydroxystilbene,Resveratrol, (Z)-,Resveratrol-3-sulfate,SRT 501,SRT-501,SRT501,cis-Resveratrol,trans-Resveratrol,trans-Resveratrol-3-O-sulfate,Resveratrol 3 sulfate,cis Resveratrol,trans Resveratrol,trans Resveratrol 3 O sulfate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013267 Stilbenes Organic compounds that contain 1,2-diphenylethylene as a functional group. Stilbene,Stilbene Derivative,Stilbene Derivatives,Stilbenoid,Stilbenoids,Derivative, Stilbene,Derivatives, Stilbene
D014920 Wine Fermented juice of fresh grapes or of other fruit or plant products used as a beverage. Wines
D055502 Secondary Prevention The prevention of recurrences or exacerbations of a disease or complications of its therapy. Disease Prevention, Secondary,Early Therapy,Relapse Prevention,Secondary Disease Prevention,Disease Preventions, Secondary,Early Therapies,Prevention, Relapse,Prevention, Secondary,Prevention, Secondary Disease,Preventions, Relapse,Preventions, Secondary,Preventions, Secondary Disease,Relapse Preventions,Secondary Disease Preventions,Secondary Preventions,Therapies, Early,Therapy, Early

Related Publications

João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
June 2016, Obstetrics and gynecology clinics of North America,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
April 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
March 2020, South Dakota medicine : the journal of the South Dakota State Medical Association,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
December 2024, Current atherosclerosis reports,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
January 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
August 2016, Texas Heart Institute journal,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
February 2011, Cardiology clinics,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
June 2016, Nihon rinsho. Japanese journal of clinical medicine,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
January 2000, Boletin de la Asociacion Medica de Puerto Rico,
João Tomé-Carneiro, and Manuel Gonzálvez, and Mar Larrosa, and María J Yáñez-Gascón, and Francisco J García-Almagro, and José A Ruiz-Ros, and Francisco A Tomás-Barberán, and María T García-Conesa, and Juan Carlos Espín
February 2021, The Cochrane database of systematic reviews,
Copied contents to your clipboard!